BEAT-MS: new trial to compare efficacy and costs of stem cell treatment for MS versus gold-standard biologics

Written by Ilana Landau, Editor

A new study, funded by the National Institutes of Health (MD, USA), will investigate the comparative effectiveness of an experimental hematopoietic stem cell treatment versus the current gold-standard biologic therapies for certain individuals with severe forms of relapsing multiple sclerosis. Researchers from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health (MD, USA), have launched the BEst Available Therapy versus autologous hematopoietic stem cell transplant for Multiple Sclerosis (BEAT-MS) trial. This new study will investigate the comparative safety, efficacy and cost—effectiveness of an experimental stem cell treatment versus current gold-standard biologic therapies for...

To view this content, please register now for access

It's completely free